OneMedNet Corp (ONMD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$0.68+16.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Revenue stabilizes near $96,000 or higher: metric not reported.
OneMedNet is cutting losses from -$3.15M to -$2.55M. Bookings passed $3M this year, beating last year. The new equity deal gives cash to support growth.
Revenue dropped sharply from $890K to $96K in one quarter. The company is still losing money. Nasdaq delisting risk shows weak business health.
The market prices in a turnaround but at a very low valuation. Our fair value is about $0.21, reflecting high risk and optionality.
Breaks if: Operating loss worsens beyond -$2.55 million next quarter
Breaks if: Equity funding agreement is terminated or fails to close
Revenue falls below $96,000 next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with high risk. The current thesis state is cautious, as the company is loss-making and has faced recent management and quality declines.
The market appears to be pricing in a high level of fragility due to ONMD's expensive valuation compared to peers. There is an expectations gap indicating that the market may not fully reflect the company's current challenges.
Fundamentals are likely to remain under pressure in the near term as the company works to reduce operating losses and improve financial performance. Recent revenue growth is positive, but operating losses persist, indicating a need for continued focus from management.
The long-term thesis hinges on the performance of sector bellwethers and the overall healthcare market. If these companies continue to perform well, it could provide a favorable environment for ONMD. Conversely, any signs of weakening in the sector could negatively impact ONMD's prospects.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company secured a new AI drug development data agreement. This partnership enhances growth potential and aligns with the company's objectives. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1-3 years, ONMD's outlook will depend heavily on its ability to navigate financial challenges and regulatory compliance while leveraging sector momentum. Not investment advice.